The Future of AMD Treatment: Faricimab and the Push for Extended Intervals
For millions grappling with neovascular age-related macular degeneration (nAMD), the prospect of less frequent eye injections is a game-changer. Recent real-world data from Switzerland, analyzing a year of treatment with faricimab (Vabysmo), suggests that extending those intervals – potentially to 12 weeks or longer for nearly 40% of patients – isn’t just a clinical possibility, but an increasingly attainable reality. This shift isn’t merely about convenience; it’s about reducing treatment burden, improving patient quality of life, and optimizing resource allocation within ophthalmology practices.
Faricimab: A Dual Pathway Approach to nAMD
Traditional anti-VEGF therapies have revolutionized nAMD treatment, but often require frequent injections to maintain visual stability. Faricimab, a bispecific antibody targeting both vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2), represents a novel approach. By simultaneously addressing these two key pathways involved in nAMD pathology, it aims to provide more durable treatment effects. The study, published in Ophthalmology and Therapy, retrospectively analyzed data from 130 eyes of 118 patients treated with Vabysmo between May 2022 and October 2024.
Real-World Results: Visual Acuity, Fluid Resolution, and Interval Extension
The findings are encouraging. Average best-corrected visual acuity (BCVA) improved significantly after 12 months of treatment (P < .001), and central retinal thickness decreased substantially (P < .001). Importantly, over half of the patients with retinal fluid at the study’s outset achieved complete fluid resolution by the 12-month mark. While the average treatment interval extended to 10.5 weeks, a substantial proportion of patients – 39.2% – reached intervals of 12 weeks or longer. These results align with, though are slightly more conservative than, those observed in pivotal randomized trials.
Why the Difference? The Nuances of Real-World Practice
The study authors acknowledge that the lower percentage of patients achieving very extended injection intervals compared to clinical trials likely reflects the individualized nature of real-world practice. Treatment decisions were guided by optical coherence tomography (OCT) and clinical exam findings, rather than a rigid, protocol-driven dosing algorithm. This highlights a crucial point: successful nAMD management isn’t a one-size-fits-all equation. Early structural improvements, the study noted, didn’t always reliably predict long-term response, reinforcing the need for careful, individualized monitoring.
Implications for Optometrists and Patient Counseling
As often the first point of contact for patients with nAMD, optometrists play a vital role in detection, referral, and patient education. These findings provide valuable information for counseling patients about treatment expectations. The potential for longer intervals between treatments, while maintaining visual outcomes, can significantly reduce patient burden and clinic demands. Learn more about AMD from the American Academy of Ophthalmology.
Looking Ahead: The Need for Long-Term, Diverse Studies
While promising, this retrospective study has limitations, including a relatively small sample size and a one-year follow-up period. The lack of data on racial demographics and lesion types also prevents a deeper understanding of treatment variations across diverse populations. Future prospective, multicenter studies are crucial to identify which patient groups benefit most from faricimab and to optimize treatment regimens for sustained visual outcomes. The ultimate goal is to personalize nAMD treatment, maximizing efficacy while minimizing the burden on both patients and healthcare systems.
What are your experiences with extended-interval treatment for nAMD? Share your insights and perspectives in the comments below!
